|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.
|
31372000 |
2019 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma.
|
26065479 |
2015 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human CD3+CD8+ lymphocytes expressing anti-CD19 CIR mRNA inhibited Daudi lymphoma growth in NOD=SCID mice.
|
19025415 |
2009 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients and Methods We treated 22 patients with advanced-stage lymphoma in a clinical trial of CAR-19 T cells preceded by low-dose chemotherapy.
|
28291388 |
2017 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early trials with anti-CD19 CAR T cells have achieved spectacular remissions in B-cell leukemia and lymphoma, so far refractory, very recently resulting in the Food and Drug Administration approval of CD19 CAR T cells for therapy.
|
29620951 |
2018 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings define a new and novel c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression.
|
22826319 |
2012 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity.
|
15507526 |
2005 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.
|
29367945 |
2018 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, one case of nasal lymphoma with CD2+CD3(Leu4)+CD8+CD19-CD56+ phenotype expressed full-length Talpha, Tbeta, and Tgamma transcripts rearranged TCR beta, gamma, and deleted TCR delta genes, indicating T-lineage, These results support the view that nasal lymphomas can separated into NK-cell and T-cell neoplasms, based on differences genotypic characteristics.
|
8698315 |
1996 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma.
|
29685162 |
2018 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
|
30097433 |
2018 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-CAR T cells engineered with our enhanced SB approach conferred potent reactivity in vitro and eradicated lymphoma in a xenograft model in vivo.
|
27491640 |
2017 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-targeted CAR-T is an effective modality in treating refractory B-cell malignancies including leukemia and lymphoma.
|
28762313 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to recent developments in therapeutic engineered T cell and effective responses of CD19-directed chimeric antigen receptor T cells (CART19) in patients with B-cell leukemia and lymphoma, adoptive T cell immunotherapy, particularly CAR-T cell therapy became a rapidly growing field in cancer therapy and recently Kymriah and Yescarta (CD19-directed CAR-T cells) were approved by FDA.
|
30261221 |
2018 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that UCB-19BBzeta and UCB-28BBzeta T cells exhibited more cytotoxicity to CD19(+) leukemia and lymphoma cell lines than UCB-19zeta and UCB-1928zeta, although differences in secretion of interleukin-2 and interferon-gamma by these T cells were not evident.
|
19719389 |
2010 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive therapy using purified T(CM) cells is now the subject of a Food and Drug Administration-authorized clinical trial for the treatment of CD19(+) B-cell malignancies, and 3 clinical cell products expressing a CD19-specific CAR for IND #14645 have already been successfully generated from lymphoma patients using this manufacturing platform.
|
23090078 |
2013 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients.
|
30809033 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use.
|
30622115 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of double staining with CD 5/CD 19 antibodies accompanied by two-color flow cytometric analysis clearly defined the chronic lymphocytic leukemia population and separated it from the lymphoma population.
|
2361698 |
1990 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma.
|
31429760 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data provide evidence that CD19 plays an important role in transmitting survival and proliferation signals downstream of CD40 and therefore might be an interesting therapeutic target for the treatment of lymphoma undergoing chronic CD40 signaling.
|
24938766 |
2014 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma.
|
30198955 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
|
31690821 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The engineered CD4(+) T cells and CD8(+) T cells both exhibited specific cytotoxicity against CD19(+) leukemia and lymphoma cell lines, as well as against CD19 transfectants, and produced high-levels of antigen-dependent Th1 (but not Th2) cytokines.
|
18227839 |
2008 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used T cells that were retrovirally transduced with this CAR to treat mice bearing a syngeneic lymphoma that naturally expressed the self-antigen murine CD19.
|
20631379 |
2010 |